Fascaplysin Sensitizes Anti-Cancer Effects of Drugs Targeting AKT and AMPK
Fascaplysin, a natural product isolated from marine sponges, is a potential candidate for the development of anti-cancer drugs. However, the mechanism underlying its therapeutic effect of strengthening anti-cancer efficacy of other drugs is poorly understood. Here, we found that fascaplysin increases phosphorylation of protein kinase B (PKB), also known as AKT, and adenosine monophosphate-activated protein kinase (AMPK), which are considered therapeutic targets for cancer treatment due to their anti-apoptotic or pro-survival functions in cancer. A cell viability assay revealed that pharmacological suppression of AKT using LY294002 enhanced the anti-cancer effect of fascaplysin in various cancer cells. Similarly, fascaplysin was observed to have improved anti-cancer effects in combination with compound C, a selective AMPK inhibitor. Another challenge showed that fascaplysin increased the efficacy of methotrexate (MTX)-mediated cancer therapy by suppressing genes related to folate and purine metabolism. Overall, these results suggest that fascaplysin may be useful for improving the anti-cancer efficacy of targeted anti-cancer drugs, such as inhibitors of phosphoinositide 3-kinase AKT signaling, and chemotherapeutic agents, such as MTX..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Molecules - 23(2017), 1, p 42 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Taek-In Oh [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.3390/molecules23010042 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ077793242 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ077793242 | ||
| 003 | DE-627 | ||
| 005 | 20230501190347.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/molecules23010042 |2 doi | |
| 035 | |a (DE-627)DOAJ077793242 | ||
| 035 | |a (DE-599)DOAJ816353b47a0a44df87a8f8a303ca77f0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QD241-441 | |
| 100 | 0 | |a Taek-In Oh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fascaplysin Sensitizes Anti-Cancer Effects of Drugs Targeting AKT and AMPK |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Fascaplysin, a natural product isolated from marine sponges, is a potential candidate for the development of anti-cancer drugs. However, the mechanism underlying its therapeutic effect of strengthening anti-cancer efficacy of other drugs is poorly understood. Here, we found that fascaplysin increases phosphorylation of protein kinase B (PKB), also known as AKT, and adenosine monophosphate-activated protein kinase (AMPK), which are considered therapeutic targets for cancer treatment due to their anti-apoptotic or pro-survival functions in cancer. A cell viability assay revealed that pharmacological suppression of AKT using LY294002 enhanced the anti-cancer effect of fascaplysin in various cancer cells. Similarly, fascaplysin was observed to have improved anti-cancer effects in combination with compound C, a selective AMPK inhibitor. Another challenge showed that fascaplysin increased the efficacy of methotrexate (MTX)-mediated cancer therapy by suppressing genes related to folate and purine metabolism. Overall, these results suggest that fascaplysin may be useful for improving the anti-cancer efficacy of targeted anti-cancer drugs, such as inhibitors of phosphoinositide 3-kinase AKT signaling, and chemotherapeutic agents, such as MTX. | ||
| 650 | 4 | |a fascaplysin | |
| 650 | 4 | |a AKT | |
| 650 | 4 | |a AMPK | |
| 650 | 4 | |a chemoresistance | |
| 650 | 4 | |a cancer | |
| 653 | 0 | |a Organic chemistry | |
| 700 | 0 | |a Jun Ho Lee |e verfasserin |4 aut | |
| 700 | 0 | |a Seongman Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Taek-Jin Nam |e verfasserin |4 aut | |
| 700 | 0 | |a Young-Seon Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Byeong Mo Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Woo Jong Yim |e verfasserin |4 aut | |
| 700 | 0 | |a Ji-Hong Lim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Molecules |d MDPI AG, 2003 |g 23(2017), 1, p 42 |w (DE-627)DOAJ000105902 |x 14203049 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2017 |g number:1, p 42 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/molecules23010042 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/816353b47a0a44df87a8f8a303ca77f0 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/1420-3049/23/1/42 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1420-3049 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2017 |e 1, p 42 | ||